Does lead interfere with hemoglobin-based oxygen carrier (HBOC) function? A pilot study of lead concentrations in three approved or tested HBOCs and oxyhemoglobin dissociation with HBOCs and/or bovine blood with varying lead concentrations

Anesthesia and Analgesia

Volumn 96, Issue 6, 2003, Pages 1813-1820

  Khan, Ahsanul K ^a   Jahr, Jonathan S ^a,b,f   Nesargi, Susmita ^a   Rothenberg, Stephen J ^a,c   Tang, Zuping ^d   Cheung, Anthony ^d   Gunther, Robert A ^d   Kost, Gerald J ^d   Driessen, Bernd ^e  

^a CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON DIOXIDE; HEMOGLOBIN; HEMOGLOBIN BASED OXYGEN CARRIER; HEMOGLOBIN GLUTAMER 200; HEMOGLOBIN GLUTAMER 250; HEMOGLOBIN RAFFIMER; LEAD; NITROGEN; OXYGLOBIN; OXYHEMOGLOBIN; POLYMERIZED HEMOGLOBIN; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD; BLOOD BANK; BLOOD SAMPLING; CATTLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG APPROVAL; DRUG SCREENING; IN VITRO STUDY; LEAD BLOOD LEVEL; NONHUMAN; NONLINEAR REGRESSION ANALYSIS; OXIMETRY; OXYGEN AFFINITY; OXYGEN CONCENTRATION; OXYGEN DISSOCIATION CURVE; OXYGEN SATURATION; OXYGEN TENSION; OXYGEN TRANSPORT; OXYGENATION; PILOT STUDY; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TONOMETER;

EID: 0038024158     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/01.ANE.0000062517.13989.B5     Document Type: Article

References (24)

1. Klein HG. The prospects for red-cell substitutes. N Engl J Med 2000;342:1666-8.
2. Jahr JS, Nesargi S, Lewis K, Johnson CJ. Blood substitutes and oxygen therapeutics: an overview and current status. Am J Ther 2002;9:437-43.
3. Driessen B, Jahr JS, Lurie F, et al. Effects of hemoglobin-based oxygen carrier hemoglobin glutamer-200 (bovine) on intestinal perfusion and oxygenation in a canine hypovolemia model. Br J Anaesth 2001;86:683-92.
4. Cheung ATW, Jahr JS, Driessen B, et al. The effects of hemoglobin glutamer-200 (bovine) on the microcirculation in a canine hypovolemia model: a noninvasive computer-assisted intravital microscopy study. Anesth Analg 2001;93:832-8.
5. Jahr JS, Lurie F, Xi S, et al. A novel approach to measuring circulating blood volume: use of a hemoglobin-based oxygen carrier (HBOC) in a rabbit model. Anesth Analg 2001;92:609-14.
6. McQuirter JL, Rothenberg SJ, Dinkins GA, et al. The effects of retained lead bullets on body lead burden. J Trauma 2001;50:892-9.
7. Bulleova S, Rothenberg JS, Manalo MA. Lead concentrations in blood bank blood. Arch Environ Health 2001;56:312-3.
8. Lewis K, Dinkins G, McQuirter J, et al. Do varying lead levels interfere with coagulation? An in vitro thrombelastography (TEG) study with whole blood. Anesth Analg 2003;96(suppl):S-154.
9. McQuirter JL, Rothenberg SJ, Dinkins GA, et al. Elevated blood lead resulting from maxillofacial gunshot injuries with lead ingestion. J Oral Maxillofac Surg. In press.
10. Jahr JS, Lurie F, Driessen B, et al. Oxygen saturation measurements in canine blood containing hemoglobin glutamer-200 (bovine): in vitro validation of the NOVA co-oximeter. Vet Clin Pathol 2001;30:39-45.
11. Lurie F, Driessen B, Jahr JS, et al. Validity of arterial and mixed venous oxygen saturation measurements in a canine hemorrhage model after resuscitation with varying concentrations of hemoglobin-based oxygen carrier (HBOC). Anesth Analg 2003;96:46-50.
12. Jahr JS, Lurie F, Gosselin R, et al. Effects of hemoglobin glutamer-250 (bovine) (HBOC-201, Hemopure) on coagulation testing. Am J Ther 2002;9:431-6.
13. Lurie F, Jahr JS, Driessen B. The novel HemoCue® Plasma/Low Hemoglobin System accurately measures low concentrations of three different hemoglobin-based oxygen carriers (HBOC) in plasma: hemoglobin glutamer-200 (bovine) (Oxyglobin®), hemoglobin glutamer-250 (bovine) (Hemopure®), and hemoglobinraffimer (Hemolink™).
14. Kelman GR. Digital computer subroutine for the conversion of oxygen tension into saturation. J Appl Physiol 1966;21:1375-6.
15. Gustin P, Clerbaux T, Willems E, et al. Oxygen transport properties of blood in two different bovine breeds. Comp Biochem Physiol A 1988;89:553-8.
16. Alavash AI, Summers AG, Wood F, Jia Y. Effects of glutaraldehyde polymerization on oxygen transport and redox properties of bovine hemoglobin. Arch Biochem Biophys 2001;391:225-34.
17. Nagababu E, Ramasamy S, Rifkind JM, et al. Site-specific crosslinking of human and bovine hemoglobins differentially alters oxygen binding and redox side reactions producing rhombic heme and heme degradation. Biochemistry 2002;41:7407-15.
18. Jahr JS. A novel blood substitute: use of HBOC-201 (Hemopure®) to decrease need for RBC - results of pivotal trial in orthopedic surgery patients [abstract]. Crit Care Med 2002;29:S243.
19. Jahr JS, Dulchavsky SA, Garino JP, et al. Hemodynamic effects of hemoglobin glutamer-250 (Hemopure®, HBOC-201) compared to red blood cells in pivotal safety and efficacy study in orthopedic surgery patients [abstract]. Anesth Analg 2002;94:S330.
20. Jahr JS, Stewart LM, MacKenzie C, et al. Pivotal phase III study: safety of polymerized bovine hemoglobin (HBOC-201, Hemopure®) as compared to RBC in patients undergoing orthopedic surgery [abstract]. Anesthesiology 2002;96:A243.
21. Pirkle JL, Kaufmann RB, Brody DJ, et al. Exposure of the U.S. population to lead, 1991-1994. Environ Health Perspect 1998;106:745-50.
22. Manton WI, Rothenberg SJ, Manalo M. The lead content of blood serum. Environ Res 2001;86:263-73.
23. Bergdahl IA, Grubb A, Schutz A, et al. Lead binding to deltaaminolevulinic acid dehydratase (ALAD) in human erythrocytes. Pharmacol Toxicol 1997;81:53-8.
24. Vandegriff KD, Rohlfs RJ, Magde MD Jr, Winslow RM. Hemoglobin-oxygen equilibrium curves measured during enzymatic oxygen consumption. Anal Biochem 1998;256:107-16.